GlassScriptPhysician profile
Zaigham H Ansari
NPI 1720097744
$4,015.59
in general payments reported to CMS, 2019-2025
27 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,603 · 2020: $222 · 2021: $19.07 · 2022: $161 · 2023: $716 · 2024: $800 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $620.31 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $481.30 | 2019-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $379.36 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $322.69 | 2019-2025 | Ingrezza |
| Corium, LLC | $292.25 | 2022-2025 | Azstarys, Azstarys |
| Lundbeck LLC | $278.78 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $259.65 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $247.26 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $207.36 | 2019-2023 | Austedo Xr |
| Neos Therapeutics, LP | $201.15 | 2019-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $104.06 | 2019-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $88.43 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Collegium Pharmaceutical, INC. | $86.56 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.42 | 2025 | Caplyta |
| Shire North American Group INC | $64.37 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $63.58 | 2019-2025 | Relexxii |
| Axsome Therapeutics, INC. | $50.78 | 2023-2024 | Sunosi, Auvelity |
| Arbor Pharmaceuticals, INC. | $30.06 | 2019 | |
| Abbvie INC. | $25.11 | 2023 | Vraylar |
| Adlon Therapeutics L.P. | $23.87 | 2020 | |
| Tempus Ai, INC | $20.79 | 2024 | Tempus Pixel |
| Bausch Health US, LLC | $18.83 | 2023 | Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $17.95 | 2025 | Cobenfy |
| Harmony Biosciences LLC | $14.86 | 2023 | Wakix |
| Alkermes, INC. | $14.17 | 2019 | |
| Owp Pharmaceuticals, INC. | $11.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaigham Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.